-
- Jana S. Burchfield
- From the Texas Heart Institute, Houston, TX (J.B.); and Departments of Internal Medicine (Cardiology) (M.X., J.A.H.) and Molecular Biology (J.A.H.), University of Texas Southwestern Medical Center, Dallas.
-
- Min Xie
- From the Texas Heart Institute, Houston, TX (J.B.); and Departments of Internal Medicine (Cardiology) (M.X., J.A.H.) and Molecular Biology (J.A.H.), University of Texas Southwestern Medical Center, Dallas.
-
- Joseph A. Hill
- From the Texas Heart Institute, Houston, TX (J.B.); and Departments of Internal Medicine (Cardiology) (M.X., J.A.H.) and Molecular Biology (J.A.H.), University of Texas Southwestern Medical Center, Dallas.
書誌事項
- タイトル別名
-
- Mechanisms: Part 1 of 2
説明
<jats:p>Despite declines in heart failure morbidity and mortality with current therapies, rehospitalization rates remain distressingly high, substantially affecting individuals, society, and the economy. As a result, the need for new therapeutic advances and novel medical devices is urgent. Disease-related left ventricular remodeling is a complex process involving cardiac myocyte growth and death, vascular rarefaction, fibrosis, inflammation, and electrophysiological remodeling. Because these events are highly interrelated, targeting a single molecule or process may not be sufficient. Here, we review molecular and cellular mechanisms governing pathological ventricular remodeling.</jats:p>
収録刊行物
-
- Circulation
-
Circulation 128 (4), 388-400, 2013-07-23
Ovid Technologies (Wolters Kluwer Health)
